{"schema_version":"1.0","type":"article","title":"Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D","url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.md","lang":"en","date":"2026-09-25","publish_at":"2026-09-25T08:00:00+08:00","updated_at":"2026-09-25","category":"商業分析系列","topic":"商業分析系列","tags":["Novo Nordisk","Anthropic","AI drug discovery","R&D workflows","Taiwan biotech"],"summary":"Novo Nordisk's collaboration with Anthropic tests scientific reasoning and R&D software engineering alongside capabilities provided by Valo, OpenAI and AWS. This analysis examines workflows, computational acceleration and collaboration economics, while distinguishing Taiwanese platform capabilities from proven partnerships and the experimental and clinical gates that remain.","key_points":[],"facts":[],"sections":["Primary sources"],"references":[{"title":"Novo Nordisk and Anthropic, September 16, 2026: Claude models and Claude Science for R&D scientific reasoning and AI-driven software engineering, with data governance and human oversight.","source":"","date":"","url":""},{"title":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916768","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916768"},{"title":"Novo Nordisk and OpenAI, April 14, 2026: pilots in R&D, manufacturing and commercial operations; integration targeted by the end of 2026, not reported as already completed.","source":"","date":"","url":""},{"title":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916532","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916532"},{"title":"Novo Nordisk and AWS, August 10, 2026: preferred cloud provider and strategic AI partner, London co-innovation hub, Amazon Bio Discovery, Amazon Bedrock and AgentCore.","source":"","date":"","url":""},{"title":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916594","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916594"},{"title":"Expanded Novo Nordisk–Valo collaboration, January 8, 2025: up to 20 programs; up to US$190 million in upfront payment, equity investment and potential near-term milestones combined; approximately US$4.6 billion in additional potential milestones, with research funding and potential royalties separate.","source":"","date":"","url":""},{"title":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085"},{"title":"Original Valo–Novo collaboration: release body dated September 25, 2023; page header dated September 24. Opal, real-world patient data, small-molecule discovery and human tissue models; three preclinical cardiovascular programs licensed.","source":"","date":"","url":""},{"title":"https://www.valohealth.com/press/valo-health-and-novo-nordisk-to-collaborate-to-discover-and-develop-novel-treatments-for-cardiometabolic-diseases-using-human-data-and-artificial-intelligence","source":"","date":"","url":"https://www.valohealth.com/press/valo-health-and-novo-nordisk-to-collaborate-to-discover-and-develop-novel-treatments-for-cardiometabolic-diseases-using-human-data-and-artificial-intelligence"},{"title":"Anthropic biomolecular-model research, September 17, 2026: more than 30 open-source models; approximately fourfold average speedup allowing small accuracy differences, close to twofold with identical outputs, and about 1.6-fold for the structure-prediction subgroup. Model-inference evaluation, not drug-development or Novo clinical success.","source":"","date":"","url":""},{"title":"https://www.anthropic.com/research/claude-uplifts-biomolecular-modeling?s=04","source":"","date":"","url":"https://www.anthropic.com/research/claude-uplifts-biomolecular-modeling?s=04"},{"title":"ITRI AIDD: SEAL target discovery, CTag molecular design, AI and reinforcement learning for candidate generation, evaluation and optimization. Undated technical page; reviewed September 20, 2026.","source":"","date":"","url":""},{"title":"https://www.itri.org.tw/english/ListStyle.aspx?DisplayStyle=01_content&MGID=1344554772173157534&MmmID=1037333532373240766&SiteID=1","source":"","date":"","url":"https://www.itri.org.tw/english/ListStyle.aspx?DisplayStyle=01_content&MGID=1344554772173157534&MmmID=1037333532373240766&SiteID=1"},{"title":"Repurgenesis: AI-powered technologies and platforms for drug repurposing. Undated platform page; reviewed September 20, 2026.","source":"","date":"","url":""},{"title":"https://repurgenesis.com/tw","source":"","date":"","url":"https://repurgenesis.com/tw"},{"title":"Topmunnity Therapeutics: AI-driven antibody discovery and engineering platform. Undated homepage; reviewed September 20, 2026.","source":"","date":"","url":""},{"title":"https://www.topmunnity.com/","source":"","date":"","url":"https://www.topmunnity.com/"}],"images":[{"alt":"Four parallel capability rows show Valo for human data and drug discovery, OpenAI for AI tools and workflow support, AWS for cloud and AI infrastructure, and Anthropic for scientific reasoning and software engineering. Four independent arrows lead to the Novo R&D workflow. There are no arrows between suppliers. A bottom note identifies this as a capability schematic, not proven clinical outcomes.","url":"https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/01_ParallelCapabilities_EN_v1.png"},{"alt":"Three parallel panels show data and a scientist exploring targets and candidates; clinical documents, manufacturing and supply-chain operations; and protein structures, molecular models and software tools. A bottom statement says experiments and clinical validation are still required.","url":"https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/02_ThreeValueLayers_EN_v1.png"},{"alt":"Three columns show OpenAI and Anthropic models and tools, AWS cloud and data services, and Valo drug discovery. The Valo column separates equity financing from collaboration payments. The bottom distinguishes potential value, cash received and recognized revenue.","url":"https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/03_RolesAndPayments_EN_v1.png"},{"alt":"Six R&D stages follow a serpentine path from data and hypotheses through AI screening, experiments, preclinical work, clinical trials and regulation/payment. An early-stage decision-speed cue is separate from later locked evidence requirements for human data, safety, efficacy and payment. No clinical stage is bypassed.","url":"https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/04_ValidationGates_EN_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/01_ParallelCapabilities_EN_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-25）。Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D。https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}